Salemonline Journal

Friedreich’s Ataxia Pipeline Report, 2023 Updates: Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs| Key Companies – Design Therapeutics, AavantiBio, Larimar

 Breaking News
  • No posts were found

Friedreich’s Ataxia Pipeline Report, 2023 Updates: Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs| Key Companies – Design Therapeutics, AavantiBio, Larimar

May 23
23:32 2023
Friedreich’s Ataxia Pipeline Report, 2023 Updates: Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs| Key Companies - Design Therapeutics, AavantiBio, Larimar
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Friedreich’s Ataxia pipeline constitutes 10+ key companies continuously working towards developing 10+ Friedreich’s Ataxia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Friedreich’s Ataxia Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Friedreich’s Ataxia Market.

 

The Friedreich’s Ataxia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Friedreich’s Ataxia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Friedreich’s Ataxia treatment therapies with a considerable amount of success over the years. 
  • Friedreich’s Ataxia companies working in the treatment market are Design Therapeutics, AavantiBio, Larimar Therapeutics, Minoryx Therapeutics, Metro International Biotech, LLC, Retrotope, Reata Pharmaceuticals, and others, are developing therapies for the Friedreich’s Ataxia treatment 
  • Emerging Friedreich’s Ataxia therapies such as – SynTEFs, FXN gene therapy, CTI-1601, MIN-102, MIB-626, RT001, Omaveloxolone, and others are expected to have a significant impact on the Friedreich’s Ataxia market in the coming years.   

 

Friedreich’s Ataxia Overview

A neurodegenerative mobility disorder with a typical onset between the ages of 10 and 15, Friedreich’s ataxia (FRDA) is hereditary and progressive. Initial signs and symptoms may include shaky gait, frequent falls, and progressive difficulty walking as a result of ataxia, which is an impairment in the capacity to coordinate voluntary movements.

 

Get a Free Sample PDF Report to know more about Friedreich’s Ataxia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight

 

Emerging Friedreich’s Ataxia Drugs Under Different Phases of Clinical Development Include:

  • SynTEFs: Design Therapeutics
  • FXN gene therapy: AavantiBio
  • RT 001: Retrotope
  • Leriglitazone: Minoryx Therapeutics
  • CTI-1601: Larimar Therapeutics
  • MIN-102: Minoryx Therapeutics
  • MIB-626: Metro International Biotech, LLC
  • RT001: Retrotope
  • Omaveloxolone: Reata Pharmaceuticals

 

Route of Administration

Friedreich’s Ataxia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

 

Friedreich’s Ataxia Pipeline Therapeutics Assessment

  • Friedreich’s Ataxia Assessment by Product Type
  • Friedreich’s Ataxia By Stage and Product Type
  • Friedreich’s Ataxia Assessment by Route of Administration
  • Friedreich’s Ataxia By Stage and Route of Administration
  • Friedreich’s Ataxia Assessment by Molecule Type
  • Friedreich’s Ataxia by Stage and Molecule Type

 

DelveInsight’s Friedreich’s Ataxia Report covers around 10+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Friedreich’s Ataxia product details are provided in the report. Download the Friedreich’s Ataxia pipeline report to learn more about the emerging Friedreich’s Ataxia therapies

 

Some of the key companies in the Friedreich’s Ataxia Therapeutics Market include:

Key companies developing therapies for Friedreich’s Ataxia are – Santhera Pharmaceuticals Holding AG, PTC Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Clinilabs Inc, Ixchel Pharma LLC, Larimar Therapeutics Inc, Neurocrine Biosciences Inc, Ataxia UK, Horizon Therapeutics Plc, Reata Pharmaceuticals Inc, and others

 

Friedreich’s Ataxia Pipeline Analysis:

The Friedreich’s Ataxia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Friedreich’s Ataxia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Friedreich’s Ataxia Treatment.
  • Friedreich’s Ataxia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Friedreich’s Ataxia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Friedreich’s Ataxia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Friedreich’s Ataxia drugs and therapies

 

Friedreich’s Ataxia Pipeline Market Drivers

  • Rapid research in the field of ataxia therapeutics, increasing collaborations and acquisitions among key players are some of the important factors that are fueling the Friedreich’s Ataxia Market.

 

Friedreich’s Ataxia Pipeline Market Barriers

  • However, there are currently no approved therapies for the treatment of patients with Friedreich’s ataxia and other factors are creating obstacles in the Friedreich’s Ataxia Market growth.

 

Scope of Friedreich’s Ataxia Pipeline Drug Insight    

  • Coverage: Global
  • Key Friedreich’s Ataxia Companies: Design Therapeutics, AavantiBio, Larimar Therapeutics, Minoryx Therapeutics, Metro International Biotech, LLC, Retrotope, Reata Pharmaceuticals, and others
  • Key Friedreich’s Ataxia Therapies: SynTEFs, FXN gene therapy, CTI-1601, MIN-102, MIB-626, RT001, Omaveloxolone, and others
  • Friedreich’s Ataxia Therapeutic Assessment: Friedreich’s Ataxia current marketed and Friedreich’s Ataxia emerging therapies
  • Friedreich’s Ataxia Market Dynamics: Friedreich’s Ataxia market drivers and Friedreich’s Ataxia market barriers 

 

Request for Sample PDF Report for Friedreich’s Ataxia Pipeline Assessment and clinical trials

 

Table of Contents

1

Friedreich’s Ataxia Report Introduction

2

Friedreich’s Ataxia Executive Summary

3

Friedreich’s Ataxia Overview

4

Friedreich’s Ataxia- Analytical Perspective In-depth Commercial Assessment

5

Friedreich’s Ataxia Pipeline Therapeutics

6

Friedreich’s Ataxia Late Stage Products (Phase II/III)

7

Friedreich’s Ataxia Mid Stage Products (Phase II)

8

Friedreich’s Ataxia Early Stage Products (Phase I)

9

Friedreich’s Ataxia Preclinical Stage Products

10

Friedreich’s Ataxia Therapeutics Assessment

11

Friedreich’s Ataxia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Friedreich’s Ataxia Key Companies

14

Friedreich’s Ataxia Key Products

15

Friedreich’s Ataxia Unmet Needs

16 

Friedreich’s Ataxia Market Drivers and Barriers

17

Friedreich’s Ataxia Future Perspectives and Conclusion

18

Friedreich’s Ataxia Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services